Since EAC is typically diagnosed late, with 90% of cases detected after symptoms appear, the prognosis remains poor, with less than 20% five-year survival, highlighting the urgent need for better screening tools.

Current diagnosis relies on invasive and costly endoscopy, which misses 90% of cases, emphasizing the importance of a non-invasive, affordable alternative like PromarkerEso.

The blood test demonstrates high sensitivity across all stages—81% for stage one, 91% for stage two, and 100% for advanced stages—and also detects Barrett’s Esophagus with 93% sensitivity.

Using four protein biomarkers and a proprietary algorithm, PromarkerEso provides a simple 'traffic light' risk score, making it accessible for primary care and direct-to-consumer screening.

Given the high incidence of EAC driven by lifestyle factors, the market potential for PromarkerEso is substantial, especially with plans for deployment through primary care and direct-to-consumer channels.

Compared to prostate cancer PSA testing, which has lower accuracy, PromarkerEso offers significantly better diagnostic performance, making it a promising tool for early detection.

The test is protected by patents in Europe, China, and Australia, paving the way for a significant global commercial opportunity.

Proteomics plans to launch PromarkerEso in Australia initially, with expansion into other territories, leveraging its patent protections and clinical validation.

Published in the journal Diseases of the Esophagus and presented at the ISDE World Congress, the study underscores the test's potential to revolutionize screening, especially in Western populations with high rates of GERD and Barrett’s Esophagus.

Early detection through this non-invasive blood test could dramatically improve treatment outcomes and survival rates for throat and esophageal cancers, representing a major advancement in cancer diagnostics.

Proteomics International Laboratories has announced promising clinical results for its blood test, PromarkerEso, which can accurately diagnose early-stage esophageal adenocarcinoma (EAC), often caused by GERD, with high sensitivity and specificity.

In a study of 350 participants, the test achieved an impressive area under the curve of 0.97, with sensitivity reaching 100% for early stages and high accuracy for Barrett's Esophagus, indicating its potential to detect EAC early.